Compare BSAC & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSAC | PCVX |
|---|---|---|
| Founded | 1977 | 2013 |
| Country | Chile | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3B | 7.0B |
| IPO Year | 2002 | 2020 |
| Metric | BSAC | PCVX |
|---|---|---|
| Price | $33.78 | $57.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $33.00 | ★ $88.25 |
| AVG Volume (30 Days) | 259.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $37.15 | N/A |
| Revenue Next Year | $7.52 | N/A |
| P/E Ratio | $14.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $25.85 | $31.51 |
| 52 Week High | $37.72 | $65.00 |
| Indicator | BSAC | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 42.58 |
| Support Level | $31.84 | $52.18 |
| Resistance Level | $34.23 | $58.77 |
| Average True Range (ATR) | 0.76 | 2.07 |
| MACD | -0.23 | -0.40 |
| Stochastic Oscillator | 0.32 | 9.25 |
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.